Translational research: What does it mean, what has it delivered and what might it deliver?

Current Opinion in Critical Care

Volumn 17, Issue 5, 2011, Pages 495-503

  Proudfoot, Alastair G ^a   Mcauley, Danny F ^b,c   Hind, Matthew ^a,d   Griffiths, Mark J D ^a,d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; CLINICAL DECISION MAKING; HEALTH CARE DELIVERY; HUMAN; INTENSIVE CARE; MEDICAL TECHNOLOGY; NONHUMAN; PHENOTYPE; QUALITATIVE ANALYSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; SEPSIS; TRANSLATIONAL RESEARCH; VALIDATION PROCESS;

ACUTE KIDNEY INJURY; ACUTE LUNG INJURY; BIOLOGICAL MARKERS; CRITICAL CARE; HUMANS; SEPSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80052774208     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32834a4b19     Document Type: Review

References (58)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature. J Am Med Assoc 1999; 282:771-778.
3. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007; 81:104-107. (Pubitemid 46050874)
4. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. (Pubitemid 43810035)
5. Levy MM, Macias WL, Vincent JL, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33:2194-2201.
6. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
7. Levitt JE, Gould MK, Ware LB, Matthay MA. The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med 2009; 24:151-167.
8. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137:288-296.
9. Glavan BJ, Holden TD, Goss CH, et al. Genetic variation in the FAS gene and associations with acute lung injury. Am J Respir Crit Care Med 2011; 183:356-363.
10. Altemeier WA, Zhu X, Berrington WR, et al. Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspaseindependent pathway. J Leukoc Biol 2007; 82:721-728. (Pubitemid 47367164)
11. Matute-Bello G, Lee JS, Liles WC, et al. Fas-mediated acute lung injury requires fas expression on nonmyeloid cells of the lung. J Immunol 2005; 175:4069-4075. (Pubitemid 41292070)
12. Stringer KA, Serkova NJ, Karnovsky A, et al. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma (1)H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 2011; 300:L4-L11.
13. Gharib SA, Nguyen E, Altemeier WA, et al. Of mice and men: comparative proteomics of bronchoalveolar fluid. Eur Respir J 2010; 35:1388-1395.
14. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009; 106:16357-16362.
15. Bastin AJ, Sato H, Davidson SJ, et al. Biomarkers of lung injury after one-lung ventilation for lung resection. Respirology 2011; 16:138-145.
16. Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol 2011; 22:810-820.
17. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinaseassociated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54:1012-1024.
18. Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010; 36:444-451.
19. Bagshaw SM, Bennett M, Haase M, et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus nonseptic acute kidney injury in critical illness. Intensive Care Med 2010; 36:452-461.
20. Martensson J, Bell M, Oldner A, et al. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010; 36:1333-1340.
21. Kumpers P, Hafer C, David S, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med 2010; 36:462-470.
22. Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020-1030.
23. Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011; 79:1119-1130.
24. Xiao WB, Wang QD, Xu JJ, et al. Evaluation of kidney oxygen bioavailability in acute renal failure by blood oxygen level dependent magnetic resonance imaging. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010; 39:157-162.
25. Molitoris BA, Sandoval RM. Multiphoton imaging techniques in acute kidney injury. Contrib Nephrol 2010; 165:46-53.
26. Darmon M, Schortgen F, Vargas F, et al. Diagnostic accuracy of Doppler renal resistive index for reversibility of acute kidney injury in critically ill patients. Intensive Care Med 2011; 37:68-76.
27. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010; 14:R15.
28. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217. (Pubitemid 46274517)
29. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003. (Pubitemid 43982479)
30. Karlsson S, Heikkinen M, Pettila V, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010; 14:R205.
31. Clec'h C, Ferriere F, Karoubi P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004; 32:1166-1169. (Pubitemid 38620986)
32. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-474.
33. Ware LB, Fessel JP, May AK, Roberts LJ, 2nd. Plasma biomarkers of oxidant stress and development of organ failure in severe sepsis. Shock 2011; 36:12-17.
34. Leaver SK, MacCallum NS, Pingle V, et al. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Med 2010; 36:336-341.
35. Paugam-Burtz C, Albuquerque M, Baron G, et al. Plasma proteome to look for diagnostic biomarkers of early bacterial sepsis after liver transplantation: a preliminary study. Anesthesiology 2010; 112:926-935.
36. Nakada TA, Russell JA, Boyd JH, et al. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 2010; 181:143-149.
37. Schlutter J. Therapeutics: new drugs hit the target. Nature [10.1038/474S5a] 2011; 474:S5-S7.
38. Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19:556-568.
39. Pronovost PJ,Murphy DJ,NeedhamDM. Thescience of translating research into practice in intensive care. Am J Respir Crit Care Med 2010; 182:1463-1464.
40. Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005; 171:606-615; Epub 2004 Dec 10. (Pubitemid 40365416)
41. Jacobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 2004; 30:662-670. (Pubitemid 38591217)
42. Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36:158-163. (Pubitemid 41122905)
43. Shyamsundar M, McKeown ST, O'Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009; 179:1107-1114.
44. Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl-CoA reductase inhibition for acute lung injury (The HARP study). Am J Respir Crit Care Med 2011; 183:620-626.
45. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297.
46. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789.
47. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364:1144-1153.
48. Venter JC. Multiple personal genomes await. Nature 2010; 464:676-677.
49. The human genome at ten. Nature 2010; 464:649-650.
50. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375:1525-1535.
51. Pushkarev D, Neff NF, Quake SR. Single-molecule sequencing of an individual human genome. Nat Biotechnol 2009; 27:847-850.
52. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 2009; 106:19096-19101.
53. Samani NJ, Tomaszewski M, Schunkert H. The personal genome: the future of personalised medicine? Lancet 2010; 375:1497-1498.
54. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6:287-293. (Pubitemid 46505879)
55. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173:281-287. (Pubitemid 43209082)
56. Perkins GD, Gates S, Lamb SE, et al. Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials 2011; 12:113.
57. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011. [Epub ahead of print]
58. Gehlenborg N, O'Donoghue SI, Baliga NS, et al. Visualization of omics data for systems biology. Nat Methods 2010; 7 (3 Suppl):S56-S68.